Mr. David J. Main
President & CEO
Mr. Main has over 20 years experience in the biopharmaceutical industry and brings a demonstrated ability to grow and finance pharmaceutical development companies. Mr. Main was formerly the President and CEO of INEX Pharmaceuticals Corp. from July 1999 until June 2005. From September 1996 until his appointment as CEO, he was the Company's Vice President, Corporate Development. While President and CEO, Mr. Main led the transformation of INEX from a research driven to a product focused biopharmaceutical company, advancing product development to the NDA stage and securing several significant pharmaceutical partnerships and over $100 million in equity financings. Prior to joining INEX, Mr. Main was a Vice President at QLT Inc. of Vancouver. Mr. Main was formerly a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He holds a B.Sc. (Pharmacy) and an MBA from the University of British Columbia (UBC). In 2002, Mr. Main formerly served as the Chair of LifeSciences BC (formerly BC Biotech) and currently serves on a number of private and not-for-profit Boards.
Dr. Thomas MacRury, Ph.D.
EVP & Chief Operating Officer
Dr. MacRury has over 30 years experience in the biopharmaceutical and chemical industry and brings a demonstrated ability to lead and manage large R&D teams and industrial partners. Dr. MacRury was formerly the Senior Vice President, Operations at INEX Pharmaceuticals where he was responsible for early clinical strategy (Phase I/II), CMC aspects of all INEX products in preclinical and clinical development, business development, technology development, intellectual property, and marketing activities. Dr. MacRury developed full GMP processes, including passing FDA audits, for the manufacturing and release of products and played a key role in the joint development programs with partners. Prior to joining INEX, Dr. MacRury was Senior Vice President and CTO at Pitman Moore where he was responsible for worldwide R&D activities including research, product development, registration and support, process development, quality assurance (GLP,GMP), and government affairs. Dr. MacRury directed technical staff of over 350 scientists with major R&D facilities in the United States, England, Australia, and New Zealand. He was also responsible for R&D investment, intellectual property, technology acquisition, and technical strategic planning. Dr. MacRury held previous technical and management positions at Union Carbide and International Minerals Corp and obtained his Ph.D. in Chemistry from UBC.
Dr. David Chernoff, M.D.
Chief Medical Officer
Dr. Chernoff combines the perspective of a practicing clinician with subspecialty training in rheumatology and infectious diseases with decades of biopharma industry experience. Dr. Chernoff trained in internal medicine at UCSF and was Assistant Chief of Medicine. From 1990-2000, he was Medical Director of Chiron Diagnostics, playing a pivotal role in the development of assays for HIV, HCV, HBV, and CMV. He then moved to Elan as VP of Corporate Technology, where he led the evaluation of a broad range of in-licensing opportunities. He recently spent two years as an Entrepreneur-in-Residence and one year as an operating partner at the venture firm TPG, where he was actively involved in due diligence and in incubating new companies. Dr. Chernoff has been the acting Chief Medical Officer of several startup biotech companies including XDX, CardioDx, Replidyne, Tethys Biosciences, Neuromolecular Pharmaceuticals. Dr. Chernoff received a B.S. in Biology from Yale, an M.D. from New York University, and his medical training in internal medicine, rheumatology, and infectious disease at UCSF. He has lectured broadly and published dozens of peer-reviewed articles.
Mr. Stephen Majlath, CMA
Director, Finance
Mr. Majlath is a senior financial executive with 17 years of finance experience with entrepreneurial businesses and major multi-nationals ranging from biotechnology start-ups to manufacturers. Mr. Majlath comes to Aquinox Pharmaceuticals Inc. from Ignition Point Technologies Corp. where he was the Chief Financial Officer. Prior to Ignition Point Technologies Mr. Majlath worked for Dyaptive Systems where he was the Director of Finance.
Through his career Mr. Majlath has held responsibility for a variety of functions including: finance and treasury, human resources, information technology, and operations in Canada and Eastern Europe. During his seven years with early stage technology and biotechnology companies Mr. Majlath was instrumental in securing venture financing and managing divestitures.
Dr. David Llewellyn, Ph.D.
Director, Business Operations
Dr. Llewellyn joined Aquinox in July 2007 as Manager, Business Operations and was promoted to Director in January of 2008. Responsible for the company's Business Development and Project Management activities, Dr. Llewellyn has over 5 years of experience in the Life Sciences industry. Prior to joining Aquinox, Dr. Llewellyn was the Manager of Business Development at StemCell Technologies Inc. where he was involved in the negotiation of several key company agreements. Before becoming involved in Business Development, Dr. Llewellyn worked at MethylGene as a Senior Medicinal Chemist leading a small research group that designed and developed DNA methyltransferase and kinase inhibitors. Dr. Llewellyn has a Ph.D. in Organic Chemistry from McGill University and an MBA in Strategic Management from the University of British Columbia. His is the author of 6 scientific publications and an inventor on two patents.
Mr. Lloyd Mackenzie
Director, Technical Operations
Mr. Mackenzie joined Aquinox in May 2008 as Manager, Technical Operations and was promoted to Director in December of 2008. Responsible for the company's Research and Development activities, Mr. Mackenzie has over 12 years of experience in the biopharmaceutical industry with expertise in medicinal chemistry, biochemistry and CMC. He is the author of 15 scientific publications and is an inventor on four patents. Prior to joining Aquinox, Mr. Mackenzie was a Research Scientist for Pharmaceutical Development at QLT Inc.. Prior to that, Mr. Mackenzie was a Research Scientist at Inflazyme Pharmaceuticals Inc.
Dr. Patrick Tam, Ph.D.
Director, Product Development
Dr. Tam joined in Aquinox in November 2009 as Director of Product Development, bringing with him over 15 years of experience in various stages of drug development. Prior to joining Aquinox, Dr. Tam was the Director of Nonclinical Safety Assessment at Forbes Medi-Tech where he was involved in the development of molecules for metabolic and inflammatory lung diseases, and oncological indications. Before that, he spent a decade at INEX where he focused on the preclinical pharmacology and toxicology of various agents in discovery and clinical development. Dr. Tam has a Ph.D. from the Department of Molecular Biology and Biochemistry at University of British Columbia.